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Abstract: Psoriasis is a common chronic and disabling inﬂ  ammatory disease that has an 
enormous physical, functional and psychosocial impact on patients’ quality of life. To date 
several conventional therapies are available for the treatment of this condition (eg, cyclosporine, 
methotrexate, retinoids, and psoralen plus ultraviolet A) which, although providing clinical 
response, do not maintain long-lasting disease remission and at times show poor tolerability 
with potential toxicity thus limiting their use. A challenge in psoriasis management is to utilize 
precociously an adequate therapy and to achieve effective and safe maintenance of its clear-
ance by improving both skin and joint manifestations as well as to prevent joint destruction 
and disability. Recent improvement in the knowledge of the pathogenesis of this disease was 
fundamental for the development of novel targeted treatment options that may be effective, safer 
and well tolerated on long-term administration periods, thus improving patient’s quality of life. 
These novel agents, which are called “biologics”, target speciﬁ  cally tumor necrosis factor-α 
(inﬂ  iximab, etanercept and adalimumab) or T cells (alefacept and efalizumab).
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Introduction
Psoriasis is a common, chronic, relapsing inﬂ  ammatory skin disease that can be 
associated with signiﬁ  cant morbidity. Patients affected by severe psoriasis constitute 
approximately 20%–30% of all patients with this disease and often require systemic 
treatment which has a major economic impact on the Health Service (Sampogna et al 
2004; Stern et al 2004; Smith et al 2005).
The aim of a chronic treatment is a balance between preventing disease-associated 
morbidity and disability, and minimizing side effects and organ toxicity consequent 
to prolonged use of a single agent. Standard systemic therapies available for the treat-
ment of moderate-to-severe plaque psoriasis include photochemotherapy, retinoids, 
cyclosporine, methotrexate, and fumarates. Although many patients beneﬁ  t from 
many of these therapies and are able to achieve disease control, few are ever com-
pletely disease free and some are ineligible because of side effects or comorbidities. 
In addition, the unrestricted long-term administration is not recommended due to the 
potential cumulative toxicity and the possibility of treatment-resistance (Grifﬁ  ths 
et al 2000; de Rie et al 2004; Rapp and Feldman 2004; Stern et al 2004; Saraceno 
and Grifﬁ  ths 2006).
Over the last 5–7 years, there has been a signiﬁ  cant advance in devising new drugs, 
the so-called biologics, which emerged as potentially alternative valuable therapeutic 
options for severe psoriasis and may be used safely over the long term with less toxic-
ity than other traditional systemic treatments. The recent advances in the understand-
ing of the immunopathogenesis of psoriasis and the identiﬁ  cation of key cytokines 
and immune cells, eg, tumor necrosis factor (TNF)-α and T-cells, revolutionized the 
management of this chronic disease. Biologics describe agents designed to block Biologics: Targets & Therapy 2007:1(1) 12
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speciﬁ  c molecular steps important in the pathogenesis of 
psoriasis, and include two main groups: (i) agents targeting 
the cytokine TNF-α (eg, etanercept, inﬂ  iximab, adalimumab) 
and (ii) agents targeting T cells or antigen-presenting cells 
(eg, efalizumab, alefacept) (Rapp and Feldman 2004; Papp 
2005a).
Fundamental principles of the 
immunopathogenesis of psoriasis
Psoriasis is a complex disease that is recently considered 
an immune-mediated, organ-speciﬁ  c (skin, or skin and 
joints) inflammatory condition, in which intralesional 
T lymphocytes trigger primed basal stem keratinocytes to 
proliferate and perpetuate the disease process. Moreover, 
the complex interactions between susceptibility genes, im-
munologic effector mechanisms and environmental trigger 
factors (eg, infections, antigens, drugs, physical and/or 
emotional stress) elicit the disease process in the skin. 
Although epidermal hyperproliferation and terminal dif-
ferentiation are the fundamental abnormalities in psoriatic 
skin, there is an immune-mediated inﬂ  ammatory process 
involving cytokines, chemokines, antigen-presenting cells 
(APCs), eg, Langherans cells, neutrophils and natural killer 
T cells, and mature skin-homing peripheral CD4+ and CD8+ 
T lymphocytes (Krueger et al 1984; Bhalearao and Bowcock 
1998; Gaspari 2006).
In fully developed psoriatic skin lesions, innate immune 
cells (eg, neutrophils, dendritic APCs and natural killer 
T cells), adaptive immune T cells, and an inﬂ  ammatory 
inﬁ  ltrate are found (Gaspari 2006). Both CD4+ and CD8+ 
T lymphocytes are present, with the CD4+ T lymphocytes 
being present mostly in the dermis. There are two subsets of 
CD8+ T lymphocytes: an epidermal homing subset express-
ing CD103 (integrin α E) and a subset that remains in the 
dermis, which may be in transit to or from the epidermis. 
These mature peripheral T lymphocytes in psoriatic lesions 
are skin-homing activated memory cells CLA (cutaneous 
leukocyte antigen+), HLA antigen-DR+, which express 
α/β TCR. The epidermal CD8+ T lymphocytes also express 
CD103 that allows them to interact with E-cadherin, facili-
tating their migration into the epidermis and their ability to 
bind to epidermal cells. Therefore, both CD4+ and CD8+ 
T cells respond to processed polypeptides presented by 
mature APCs in the skin. The possibilities for antigen rec-
ognition by these cells include self polypeptides (epidermal 
or keratinocyte-derived), those derived from microbial 
agents, or microbial superantigens. Psoriatic plaque devel-
opment and maintenance is dependent on the pathologic 
collaboration of T lymphocytes (CD4+ cells, CD8+ cells and 
natural killer T cells) and dendritic APCs. The APCs are 
responsible for activation of inﬁ  ltrating T cells, by cell-cell 
interactions of which immunologic synapse is central for 
antigen recognition. Antigen recognition by T lymphocytes 
requires that mature APCs process complex polypeptides, 
load them onto self-major histocompatibility complex class 
I or II molecules with a variety of costimulatory signals 
(eg, CD86, CD80, CD40, lymphocyte function-associated 
antigen-3, CD54) for which there are receptors on the sur-
face of T lymphocytes, present the processed peptides to the 
T cells, and ﬁ  nally growth factor production by the activated 
T lymphocytes (Figures 1–2) (Bhalerao and Bowcock 1998; 
Austin et al 1999; Prinz 2003; Grifﬁ  ths 2003). 
Moreover, in skin lesions and in blood there is a deﬁ  ciency 
of T-regulatory cell suppressor activity that may lead to 
unrestrained T cell proliferation and chronic overproduction 
of chemokines and Th1-derived cytokines, eg, interferon-γ, 
interleukin-2, TNF-α, etc. These proinﬂ  ammatory cytokines 
and growth factors target epidermal keratinocytes to hyper-
proliferate, develop abnormal differentiation and become 
resistant to apoptotic signals. Furthermore, epidermal hyper-
proliferation is supported by neoangiogenesis which is also 
driven by T cell-derived growth factors and inﬂ  ammatory 
cytokines (Austin et al 1999; Prinz 2003; Banchereau et al 
2004; Gaspari 2006).
TNF-α appears to be a critical cytokine in the patho-
genesis of T cell-mediated autoimmune diseases, including 
psoriasis, where it is demonstrated that it is crucial for kera-
tinocyte hyperproliferation, endothelial cell regulation, and 
recruitment/effector function of memory T cells (Vassalli 
1992; Ettehadi et al 1994; Kimber et al 2000). Moreover, 
TNF-α levels are increased in psoriatic lesions, compared 
with those in uninvolved skin in psoriatic patients and in 
the healthy skin of nonpsoriatic individuals. Serum and 
lesional TNF levels decrease after effective psoriasis therapy 
correlating with clinical improvement in the disease. These 
observations suggested the use of anti-TNF-α agents with 
the intent to interfere with the proinﬂ  ammatory effects of this 
cytokine. Therefore, several TNF-α antagonists have been 
successfully utilized for the treatment of severe psoriasis 
(Gordon and Ruderman 2006).
Targeted treatment options
Advances in the knowledge of the major role of T cells 
in the pathogenesis of psoriasis and the understanding of 
chronic inﬂ  ammatory pathways has led to the development of 
several biologic agents that may target speciﬁ  c inﬂ  ammatory Biologics: Targets & Therapy 2007:1(1) 13
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steps. Many accessory molecules involved in the so-called 
immunologic synapse, have been targeted by biologic 
therapies (alefacept and efalizumab) which showed a sig-
niﬁ  cant efﬁ  cacy in psoriasis by interfering with the effector 
CD4+ and CD8+ T lymphocyte activation and secretion of 
the cytokines (eg, IFN-γ and TNF-α) found in psoriatic 
lesions. The ﬁ  rst agent approved to treat adult patients af-
fected by moderate-to-severe plaque psoriasis was alefacept 
(Amevive®, Biogen Idec Inc.) and it is currently registered 
for use in several countries, including United States (US) 
but not the European Union (EU). Efalizumab (Raptiva®, 
Genetech, Inc.; Serono International S.A.) is also registered 
for the same indication in many countries, including US and 
EU (Ellis and Krueger 2001; Krueger et al 2002; Lebwhol 
et al 2003; Jullien et al 2004; Rapp and Feldman 2004; 
Leonardi et al 2005).
Therapeutic targeting of TNF-α with biologic agents 
such as etanercept, inﬂ  iximab, and adalimumab has proven 
the important role of this inﬂ  ammation mediator in psoriasis. 
Etanercept (Enbrel®, Amgen, Inc.; Wyeth Pharmaceuticals) is 
registered for the treatment of psoriasis and psoriatic arthritis 
(PsA) in EU and US among other countries. Another TNF-α 
antagonist, inﬂ  iximab (Remicade®, Centocor, Inc.; Schering-
Plough Corp.), has presented Phase III clinical trial data for 
the treatment of psoriasis and recently was registered for use in 
EU. Currently evaluated in Phase III clinical trials, adalimumab 
(Humira®, Abbott Laboratories) is at an earlier stage of devel-
opment for psoriasis (Leonardi et al 2003; Rapp and Feldman 
2004; Papp et al 2005a; Reich et al 2005a). (Table 1)
T cell inhibitors
Alefacept 
Alefacept is a recombinant protein that binds to CD2 on memo-
ry-effector T lymphocytes, inhibiting their activation and reduc-
ing the number of these cells. It is a fusion protein composed 
of an LFA-3 protein and human IgG1 fragment crystallizable 
(Fc) domain. The drug is administered by intramuscular (IM) 
injection or intravenous (IV) infusion. Patients treated with 
alefacept have experienced a reduction in CD45RO+ memory 
T cells, which correlates with the clinical improvement. To 
date, no clinically signiﬁ  cant signs of immunosuppression, 
opportunistic infections, or increase in malignancy have been 
observed (Ellis and Krueger 2001; Lebwhol et al 2003). 
Alefacept has been evaluated as a weekly 7.5 mg IV 
administration and as a weekly IM 15 mg injection how-
ever, only the IM dose is currently available. The efﬁ  cacy 
and safety of alefacept 15 mg, weekly administered for 
12-weeks, were evaluated in a randomized, placebo-con-
trolled, Phase III trial of adult patients with plaque psoriasis 
(body surface area >10%). Two weeks after the treatment 
Figure 1 Immunologic synapse. A: Innate T lymphocyte (T-cell)-antigen presenting cell (APC) interaction and antigen recognition. B: Activation of innate T cells into adap-
tive, Th1 (T-helper) and Tc1 (T-cytotoxic), and immunologic cascade.
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phase was completed (study week-14), the Psoriasis Area 
and Severity Index (PASI) improved by at least 75% from 
baseline (PASI-75) in 21% of the 166 patients who received 
alefacept 15 mg per week, with 42% achieving at least a 
50% improvement from baseline (PASI-50). This compares 
with rates of 5 and 18%, respectively, for patients random-
ized to placebo (n = 168; P < 0.001 for both comparisons). 
Alefacept therapy appeared to be well tolerated, even with 
long-term use (Lebwhol et al 2003). 
A multicentre (63 sites in Europe, US, and Canada), 
randomized, double-blind, placebo-controlled, parallel-group 
study, comparing 10 mg and 15 mg of alefacept and placebo 
administered IM once-weekly for 12-weeks, demonstrated 
that treatment with 15 mg of alefacept provided a higher 
PASI reduction from baseline with adverse events similar 
to that of placebo (Ortonne 2003).
The primary concern with alefacept is T lymphocyte 
depletion. Patients with CD4+ T lymphocyte counts below 
normal should not initiate therapy with alefacept. It also 
recommended to monitor twice-weekly the T cells. Weekly 
monitoring of CD4+ T cells is also recommended in patients 
treated in the United States (Papp 2005a).
Efalizumab
Efalizumab is a humanized monoclonal antibody against the 
CD11a molecule. CD11a and CD18 are subunits of leukocyte 
function-associated antigen 1 (LFA-1), a T cell surface 
molecule important in T cell activation, T cell migration 
into skin, and cytotoxic T cell function. This drug binds to 
CD11a on T cells blocking the interaction between LFA-1 
and intercellular adhesion molecule 1 (ICAM-1), its partner 
molecule for adhesion. The blockade is reversible and does 
not deplete T cells. The currently available formulation of 
efalizumab is delivered as a once-weekly subcutaneous (SC) 
injection (Jullien et al 2004). 
Multiple Phase III clinical trials have demonstrated the 
efﬁ  cacy, safety, and health-related quality-of-life (HRQOL) 
beneﬁ  ts of 12-weeks of SC efalizumab therapy (1 mg/kg/week) 
in patients with moderate-to-severe chronic plaque psoriasis. 
A total of 556 adult psoriatic patients were randomized to 
receive efalizumab (n = 369) or placebo (n = 187) double-
blind for 12-weeks; all patients were then eligible to receive 
extended efalizumab open-label treatment for an additional 
12-weeks. Efalizumab treatment showed a signiﬁ  cant effect 
relative to placebo after 12-weeks, and the extended treatment 
Figure 2 Immunopathogensis of psoriasis.
Abbreviations: Kc, keratinocyte;  APC, antigen-presenting cell; Tc1, T-cytotoxic lymphocyte; Th1, T-helper lymphocyte.
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conferred additional clinical beneﬁ  t. Efalizumab has shown 
good safety proﬁ  le and no opportunistic infections, no clinical 
signs of immunosuppression, hepatotoxicity or nephrotox-
icity associated to its use. The Phase III trials showed no 
evidence of T cell depletion or increased risk of end-organ 
toxicity, malignancy, or infection. The most common adverse 
events associated with efalizumab administration are acute 
ﬂ  u-like symptoms (eg, headache, chills, fever, myalgia, 
vomiting, and nausea) observed primarily after the ﬁ  rst two 
doses. The incidence of acute adverse events in patients 
treated with efalizumab at the following doses is compa-
rable to that observed in the placebo group. Worsening of 
psoriasis and psoriasis variants has been observed in 3% of 
efalizumab patients during therapy and in 14% of patients 
following abrupt discontinuation of efalizumab, respectively 
a generalized inﬂ  ammatory reaction and a rebound. Further-
more, new-onset or worsening arthritis has been infrequently 
reported during clinical trials (Leonardi et al 2003; Sterry 
et al 2004; Menter et al 2005a).
While the 12-week, double-blind, placebo-controlled, 
ﬁ  rst-treatment (FT) CLEAR trial period demonstrated the 
efﬁ  cacy/safety of efalizumab in moderate-to-severe plaque 
psoriasis including refractory or contraindicated patients 
for other systemic treatments, a further study of Sterry and 
colleagues (2006) assessed the efﬁ  cacy/safety during an 
open-label extended 24-week continuous treatment. Among 
efalizumab-treated patients who had <75% PASI improve-
ment at week-12 FT, extended treatment led to PASI75 in 
26.6%; patients who had PASI 50 and 75 improvement 
at week-12 FT, extended treatment led to PASI75 in 47.5%; 
among patients achieving PASI75 at week-12 FT, median 
time of relapse was 58 days; and, re-treatment after relapse 
led to an improvement of mean PASI of 62.3% from study 
baseline. Safety results were consistent of other previous 
studies and efﬁ  cacy results demonstrate additional beneﬁ  t 
of continuing efalizumab (Sterry et al 2006).
TNF-α inhibitors
Inﬂ  iximab 
Inﬂ  iximab is a chimeric monoclonal antibody that binds 
membrane-bound and soluble TNF-α. It was the ﬁ  rst blocker 
studied for the treatment of psoriasis, approved by the FDA 
to treat moderate-to-highly active rheumatoid arthritis in 
combination with methotrexate, moderate-to-highly active 
Crohn’s disease, and both rheumatoid arthritis and Crohn’s 
disease who have failed to respond to conventional therapies. 
Table 1 Biologics in psoriasis
 Class  Structure  Origin  Indications  Dosage
Alefacept    Soluble recombinant      
  T cell   fusion protein against   Humanized  Moderate-to-  15 mg/week SC 
  inhibitor  CD2 (LFA-3 protein     severe plaque   injections
    subunit + human     psoriasis 
    IgG1 fragment      
   domain)     
Efalizumab    Monoclonal antibody   Humanized  Moderate-to-  1 mg/kg/week SC 
  T cell   against the CD11a     severe plaque   injections
 inhibitor      psoriasis 
Inﬂ  iximab        Rheumatoid   3–5 mg/kg EV 
 TNF-α   Monoclonal antibody   Chimeric   arthritis, Crohn’s   infusion at time 0, 2 
 inhibitor  against  TNF-α  (human/murine)  disease,   and 6-weeks 
       moderate-to-  (induction)  and  every 
        severe plaque   8-weeks 
        psoriasis and   (maintenance) 
       psoriatic  arthritis 
Etanercept   Soluble  TNF-α     Rheumatoid  
 TNF-α   receptor (recombinant  Human  arthritis,   25–50 mg twice a 
  inhibitor   fusion protein of     moderate-to-  week SC injections
    human TNF receptor     severe plaque  
    + human IgG1)    psoriasis and  
       psoriatic  arthritis 
Adalimumab    Monoclonal antibody     Rheumatoid   40 mg once a week or
 TNF-α   against TNF-α  Human  arthritis, psoriatic   once every 2-weeks 
  inhibitor       arthritis  SC injectionsBiologics: Targets & Therapy 2007:1(1) 16
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This drug is administrated as IV infusion (Rapp and Feldman 
2004; Papp 2005a).
Efﬁ  cacy of inﬂ  iximab has been demonstrated in pso-
riasis patients in randomized, placebo-controlled Phase II 
trials. Results of an international multicenter, randomized, 
placebo-controlled Phase III trial of adult patients with plaque 
psoriasis treated with inﬂ  iximab 5 mg/kg were recently 
reported. At week-10 of treatment, the PASI-75 response 
rate was 80.4% in the inﬂ  iximab-treated group and 2.6% in 
the placebo-treated group. Response was sustained through 
week-24. However, excluding patients who missed 2 infu-
sions, the PASI-75 rate at week-50 was 70.5%. The moder-
ate reduction in efﬁ  cacy may be due to the development of 
inhibitory antibodies in a percentage of the patients (Reich 
et al 2005a). The safety proﬁ  le for inﬂ  iximab during this 
extended treatment Phase III trial appears to be comparable 
to those observed during earlier studies. The incidence of 
adverse events and serious adverse events in inﬂ  iximab-
treated patients was slightly elevated through the first 
24-weeks of treatment, and one patient who received inﬂ  ix-
imab died of sepsis. Elevations in aminotransferases were 
also observed in some inﬂ  iximab-treated patients. In this 
trial, infection rates were comparable between the treated 
and placebo groups (Reich et al 2005a).
The results of a Phase III, multicentre, double-blind clini-
cal trial which included 378 psoriatic patients demonstrated 
the effectiveness of inﬂ  iximab 5 mg/kg in both induction and 
maintenance regimen. At week-10, 80% of patients treated 
with inﬂ  iximab achieved PASI75 and 57% PASI90, com-
pared with 3% and 1% in the placebo group (p < 0.0001). At 
week-24, PASI75 and PASI90 were maintained (p < 0.0001). 
At week-50, 61% achieved PASI75 and 45% achieved 
PASI90 in the inﬂ  iximab group (Reich et al 2005b).
In a randomized comparison of continuous (every-
8-week) vs. intermittent (as-needed) inﬂ  iximab mainte-
nance regimens for the treatment of moderate-to-severe 
psoriasis demonstrated that, through week-50, response was 
best in the continuous inﬂ  iximab therapy group (Menter 
et al 2007).
It is also demonstrated that therapy with inﬂ  iximab at 
the dose of 5 mg/kg signiﬁ  cantly improves the signs and 
symptoms of arthritis, dactylitis and enthesitis in patients 
with active PsA that had been resistan to disease-modifying 
antirheumatic drugs (DMARDs). Results from the inﬂ  iximab 
multinational psoriatic arthritis controlled trial (IMPACT) 
showed that a continuous infliximab treatment led to 
sustained beneﬁ  t through 50-weeks with a favorable beneﬁ  t-
to-risk ratio (Antoni et al 2005).
Inﬂ  iximab has been associated with several adverse 
events. Infusion reactions, reported in 19% of patients in 
clinical trials, usually consist of fever or chills, chest pain, 
hypotension, hypertension, and dyspnea. Neutralizing 
antibodies are formed, and patients can develop a serum-
sickness reaction days after administration of the drug. 
Multiple reports have indicated mild and serious infections 
during treatment with inﬂ  iximab, in particular reactivation 
of latent tuberculosis (TB). The available in vitro and epi-
demiologic evidence for the TNF inhibitors (inﬂ  iximab and 
etanercept) shows that the risk of development of active TB 
is higher with inﬂ  iximab. Furthermore, a decrease of TNF-
α activity is demonstrated to be correlated with an increase 
of susceptibility to TB. The reason that only some patients 
succumb to rapidly disseminated infection is unknown, but 
may be related to the extent of TNF blockade in different in-
dividuals. This difference in inhibition may also explain why 
the incidence of TB seems to be increased with inﬂ  iximab in 
comparison with the other TNF inhibitors. However, it has 
not been observed an increased risk of serious infection in 
inﬂ  iximab-treated patients. One of the major concerns with 
the use of TNF inhibitors is the potential development of lym-
phomas. The majority of cases (81%) were non-Hodgkin’s 
lymphomas. Induction of antinuclear antibodies and anti-
DNA antibodies is observed in some patients treated with 
inﬂ  iximab and etanercept. Recently, the induction of true 
lupus erythematosus by TNF inhibitors has been observed 
(Reich et al 2005a).
Etanercept 
Etanercept is a TNF-α receptor recombinant fusion protein, 
comprising domains of the 75-kDa human TNF receptor and 
human IgG1, which competitively inhibits the interaction of 
this cytokine with cell-surface receptors and binds soluble 
TNF, preventing its mediated cellular responses and modulat-
ing the activity of other proinﬂ  ammatory cytokines regulated 
by TNF. Etanercept is self-administered as SC injections once 
or twice-weekly (Rapp and Feldman 2004; Papp 2005a).
The efﬁ  cacy and safety beneﬁ  ts of etanercept after 12 
and 24-weeks of therapy in patients with moderate-to-severe 
chronic plaque psoriasis have been demonstrated in Phase 
III clinical trials.
In the EU the recommended dosage is 25 mg administered 
SC twice-weekly for up to 24-weeks, although dosing at 
50 mg twice-weekly is also possible for the ﬁ  rst 12-weeks fol-
lowed by a dose reduction to 25 mg twice-weekly. Moreover, 
on the basis of published clinical data, European guidelines 
indicate that nonresponders should discontinue etanercept Biologics: Targets & Therapy 2007:1(1) 17
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after 12-weeks and that re-treatment is possible after discon-
tinuation. In the US, the recommended dosing of etanercept 
is 50 mg twice-weekly for the ﬁ  rst 12-weeks of treatment 
followed by 50 mg etanercept once-weekly.
A double-blind, randomized, placebo-controlled Phase 
III clinical study demonstrated the safety and efﬁ  cacy of 
12 and 24-weeks of etanercept treatment. Results showed 
that etanercept was well tolerated and the adverse events 
observed during the ﬁ  rst 12-week placebo-controlled period 
were mild-to-moderate and the etanercept and placebo groups 
showed no signiﬁ  cant differences (Leonardi et al 2003; Papp 
et al 2005b).
Etanercept has been used safely over the past few years. 
Injection-site reactions are the main adverse events noted. 
There have been observations of demyelinating disorders 
such as multiple sclerosis, allergic reactions, and aplastic 
anemia. It possesses a good safety proﬁ  le in regard to the 
risk of malignancy and infection. There was no apparent 
temporal association between the onset of clinical TB and the 
introduction of etanercept therapy. TNF antagonists might 
induce new-onset heart failure or exacerbate existing disease 
(Rapp and Feldman 2004; Papp 2005a).
The safety data from an integrated database of 1347 
patients from 3 randomized, double-blind, placebo-controlled 
clinical trials were analyzed by Gottlieb and colleagues 
(2006). Rates of adverse events in the ﬁ  rst 12-weeks of etaner-
cept monotherapy in the 3 trials were similar among all active 
groups as well as each active group compared with the placebo 
group, and no dose-related toxicities were reported.
A recent randomized, open-label study evaluated the 
effectiveness and safety of continuous versus interrupted 
etanercept therapy. All patients received uninterrupted 
etanercept 50 mg twice weekly during the ﬁ  rst 12-weeks, 
followed by either continuous or interrupted 50 mg once 
weekly in the next 12-weeks. At week-12, comparable high 
proportions of responders were in the continuous (71.3%) 
and interrupted (72%) groups. At week-24, the proportion 
of responders was greater in the continuous group (71% vs 
59.5% of the interrupted group; p < 0.0001). Both treatment 
groups were generally well tolerated (Moore et al 2007).
Adalimumab 
Adalimumab is a fully human anti-TNF-α monoclonal anti-
body administered as 40 mg subcutaneously once every other 
week. It has been approved by the FDA for the treatment of 
rheumatoid arthritis and currently being evaluated in Phase II 
and III clinical studies for the treatment of moderate-to-severe 
plaque psoriasis and PsA. These trials showed impressive 
PASI responses, with 53% of patients on 40 mg every other 
week and 80% of patients on 40 mg weekly achieving a 
75% reduction in the PASI. Adverse events reported were 
similar to placebo, with headache, injection site pain, nausea, 
elevated tryglicerides, cough, sinus congestion, and fatigue. 
Adalimumab was found to be effective for psoriasis refrac-
tory to other treatments including inﬂ  iximab and etanercept 
(Backer 2004; Chen et al 2004; Rapp and Feldman 2004; 
Menter et al 2005b; Papp 2005a; Winterﬁ  eld et al 2005).
Results of a double-blind, randomized, placebo-controlled 
study showed that patients with moderate-to-severe active 
PsA and chronic plaque psoriasis treated with adalimumab 
signiﬁ  cantly improved joint and skin manifestations, inhibited 
structural changes on radiographs, lessened disability due 
to joint damage, and improved quality of life. At week-12, 
58% of the adalimumab-treated patients achieved an ACR20 
response, compared with 14% of the placebo-treated patients 
(P < 0.001). At week-24, similar ACR20 response rates were 
maintained. Among the 69 adalimumab-treated patients evalu-
ated with the Psoriasis Area and Severity Index (PASI), 59% 
achieved a 75% PASI improvement response at 24-weeks, 
compared with 1% of the 69 placebo-treated patients evalu-
ated (P < 0.001) (Mease et al 2005).
Summary
Biologic agents appear to offer an effective and safe alter-
native to conventional systemic therapies and phototherapy 
for the treatment of moderate-to-severe psoriasis. To date, 
patients treated with inﬂ  iximab, etanercept, adalimumab, 
efalizumab, alefacept have achieved successful therapy of 
psoriasis without the organ toxicity seen with the long-term 
standard systemic treatments. However, these agents have 
potential limitations which include the expected high costs 
of treatment, lack of long-term follow-up, and the selected 
nature of the patient populations treated.
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